RhumbLine Advisers
CNCE

RhumbLine Advisers’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

RhumbLine Advisers’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-43,959
Closed -$219K – 3151
2021
Q1 		$219K Sell
43,959
-1,760
-4% -$14.2K ﹤0.01% 2807
2020
Q4 		$578K Buy
45,719
+6,213
+16% +$70.8K ﹤0.01% 2385
2020
Q3 		$388K Sell
39,506
-6,309
-14% -$62.2K ﹤0.01% 2405
2020
Q2 		$456K Buy
45,815
+5,466
+14% +$52.4K ﹤0.01% 2393
2020
Q1 		$357K Buy
40,349
+6,155
+18% +$60.7K ﹤0.01% 2323
2019
Q4 		$315K Buy
34,194
+210
+0.6% +$1.49K ﹤0.01% 2569
2019
Q3 		$200K Buy
33,984
+2,998
+10% +$31.8K ﹤0.01% 2749
2019
Q2 		$372K Buy
30,986
+243
+0.8% +$2.61K ﹤0.01% 2495
2019
Q1 		$371K Sell
30,743
-518
-2% -$7.63K ﹤0.01% 2446
2018
Q4 		$392K Buy
31,261
+9,313
+42% +$129K ﹤0.01% 2406
2018
Q3 		$326K Buy
21,948
+311
+1% +$4.89K ﹤0.01% 2473
2018
Q2 		$364K Buy
21,637
+4,124
+24% +$80.1K ﹤0.01% 2449
2018
Q1 		$401K Buy
17,513
+265
+2% +$5.89K ﹤0.01% 2299
2017
Q4 		$446K Sell
17,248
-3,200
-16% -$64.4K ﹤0.01% 2282
2017
Q3 		$302K Buy
20,448
+195
+1% +$2.83K ﹤0.01% 2551
2017
Q2 		$283K Buy
20,253
+1,500
+8% +$22.1K ﹤0.01% 2586
2017
Q1 		$320K Buy
18,753
+976
+5% +$11.7K ﹤0.01% 2473
2016
Q4 		$183K Buy
17,777
+319
+2% +$2.92K ﹤0.01% 2698
2016
Q3 		$177K Buy
17,458
+210
+1% +$2.29K ﹤0.01% 2717
2016
Q2 		$194K Buy
17,248
+2,414
+16% +$30.7K ﹤0.01% 2755
2016
Q1 		$203K Buy
14,834
+125
+0.8% +$1.8K ﹤0.01% 2729
2015
Q4 		$279K Buy
14,709
+955
+7% +$20.8K ﹤0.01% 2621
2015
Q3 		$258K Buy
13,754
+574
+4% +$9.76K ﹤0.01% 2642
2015
Q2 		$196K Buy
+13,180
New +$201K ﹤0.01% 2901

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RhumbLine Advisers's CNCE Position: Q2 2021 in Review

RhumbLine Advisers sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2021, closing a stake of 43,959 shares — an estimated $219K sold.

RhumbLine Advisers first reported a position in CNCE in Q2 2015 and held it in 24 quarters. The position peaked at $578K in Q4 2020. 79 funds tracked by Wall St. Rank hold CNCE as of Q2 2021.

  • RhumbLine Advisers reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 43,959 Concert Pharmaceuticals, Inc. shares in Q2 2021, an estimated $219K.
  • RhumbLine Advisers first reported a position in Concert Pharmaceuticals, Inc. in Q2 2015 and held it in 24 quarters.
  • RhumbLine Advisers's Concert Pharmaceuticals, Inc. position peaked at $578K in Q4 2020.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.